FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023957899> ?p ?o ?g. }

• W2023957899 endingPage "2867" @default.
• W2023957899 startingPage "2856" @default.
• W2023957899 abstract "Overexpression, or gene amplification, of the human epidermal growth factor receptor 2 (HER2) is evident in 20% to 25% of breast cancers. The biologic agent trastuzumab is an HER2-targeted monoclonal antibody that inhibits the proliferation of tumor cells and induces tumor cell death through multiple mechanisms of action. Currently, trastuzumab is approved for use in the adjuvant and metastatic settings. Trials combining trastuzumab with neoadjuvant chemotherapy suggest that patients with HER2-positive breast cancer also may benefit from preoperative trastuzumab. For this article, the author reviewed efficacy and safety data from key studies of patients who received neoadjuvant trastuzumab-based therapy. Studies were identified from literature searches of publication and congress databases. The results of 3 large phase 3 trials (the M. D. Anderson Cancer Center neoadjuvant trastuzumab trial, the Neoadjuvant Herceptin [NOAH] trial, and the German Breast Group/Gynecologic Oncology Study Group “GeparQuattro” trial) demonstrated that, compared with chemotherapy alone, neoadjuvant trastuzumab plus chemotherapy significantly increased pathologic complete response rates to as high as 65%. Improvements in disease-free, overall, and event-free survival also were reported in the NOAH trial. In addition to demonstrated efficacy, a low incidence of cardiac dysfunction suggests that neoadjuvant trastuzumab is both effective and well tolerated. Similar results have been reported in a range of phase 2 studies using different trastuzumab-based regimens. These encouraging data led the National Comprehensive Cancer Network to recommend treating patients who have operable, locally advanced, HER2-positive breast cancer with neoadjuvant paclitaxel plus trastuzumab followed by 5-fluorouracil, epirubicin, and cyclophosphamide plus trastuzumab. Cancer 2010. © 2010 American Cancer Society." @default.
• W2023957899 created "2016-06-24" @default.
• W2023957899 creator A5067601081 @default.
• W2023957899 date "2010-04-01" @default.
• W2023957899 modified "2023-09-26" @default.
• W2023957899 title "Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer" @default.
• W2023957899 cites W147476215 @default.
• W2023957899 cites W1772131958 @default.
• W2023957899 cites W1867197625 @default.
• W2023957899 cites W1933080611 @default.
• W2023957899 cites W1992234802 @default.
• W2023957899 cites W1996779786 @default.
• W2023957899 cites W2000798782 @default.
• W2023957899 cites W2024893022 @default.
• W2023957899 cites W2032037224 @default.
• W2023957899 cites W2043103956 @default.
• W2023957899 cites W2045324973 @default.
• W2023957899 cites W2057084727 @default.
• W2023957899 cites W2058085109 @default.
• W2023957899 cites W2070477834 @default.
• W2023957899 cites W2072383130 @default.
• W2023957899 cites W2080870561 @default.
• W2023957899 cites W2087179076 @default.
• W2023957899 cites W2101577390 @default.
• W2023957899 cites W2104337757 @default.
• W2023957899 cites W2116106032 @default.
• W2023957899 cites W2118806120 @default.
• W2023957899 cites W2120007701 @default.
• W2023957899 cites W2121611266 @default.
• W2023957899 cites W2128230789 @default.
• W2023957899 cites W2131915049 @default.
• W2023957899 cites W2139510434 @default.
• W2023957899 cites W2141393790 @default.
• W2023957899 cites W2149908785 @default.
• W2023957899 cites W2151809511 @default.
• W2023957899 cites W2152647863 @default.
• W2023957899 cites W2164774797 @default.
• W2023957899 cites W2171958606 @default.
• W2023957899 cites W2233806202 @default.
• W2023957899 cites W2262955759 @default.
• W2023957899 cites W2318605753 @default.
• W2023957899 cites W2331142721 @default.
• W2023957899 cites W4230950260 @default.
• W2023957899 cites W4375905852 @default.
• W2023957899 doi "https://doi.org/10.1002/cncr.25120" @default.
• W2023957899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20564392" @default.
• W2023957899 hasPublicationYear "2010" @default.
• W2023957899 type Work @default.
• W2023957899 sameAs 2023957899 @default.
• W2023957899 citedByCount "95" @default.
• W2023957899 countsByYear W20239578992012 @default.
• W2023957899 countsByYear W20239578992013 @default.
• W2023957899 countsByYear W20239578992014 @default.
• W2023957899 countsByYear W20239578992015 @default.
• W2023957899 countsByYear W20239578992016 @default.
• W2023957899 countsByYear W20239578992017 @default.
• W2023957899 countsByYear W20239578992018 @default.
• W2023957899 countsByYear W20239578992019 @default.
• W2023957899 countsByYear W20239578992020 @default.
• W2023957899 countsByYear W20239578992021 @default.
• W2023957899 countsByYear W20239578992022 @default.
• W2023957899 countsByYear W20239578992023 @default.
• W2023957899 crossrefType "journal-article" @default.
• W2023957899 hasAuthorship W2023957899A5067601081 @default.
• W2023957899 hasBestOaLocation W20239578991 @default.
• W2023957899 hasConcept C121608353 @default.
• W2023957899 hasConcept C126322002 @default.
• W2023957899 hasConcept C143998085 @default.
• W2023957899 hasConcept C2776694085 @default.
• W2023957899 hasConcept C2778292576 @default.
• W2023957899 hasConcept C2779786085 @default.
• W2023957899 hasConcept C2780835546 @default.
• W2023957899 hasConcept C530470458 @default.
• W2023957899 hasConcept C535046627 @default.
• W2023957899 hasConcept C71924100 @default.
• W2023957899 hasConceptScore W2023957899C121608353 @default.
• W2023957899 hasConceptScore W2023957899C126322002 @default.
• W2023957899 hasConceptScore W2023957899C143998085 @default.
• W2023957899 hasConceptScore W2023957899C2776694085 @default.
• W2023957899 hasConceptScore W2023957899C2778292576 @default.
• W2023957899 hasConceptScore W2023957899C2779786085 @default.
• W2023957899 hasConceptScore W2023957899C2780835546 @default.
• W2023957899 hasConceptScore W2023957899C530470458 @default.
• W2023957899 hasConceptScore W2023957899C535046627 @default.
• W2023957899 hasConceptScore W2023957899C71924100 @default.
• W2023957899 hasIssue "12" @default.
• W2023957899 hasLocation W20239578991 @default.
• W2023957899 hasLocation W20239578992 @default.
• W2023957899 hasOpenAccess W2023957899 @default.
• W2023957899 hasPrimaryLocation W20239578991 @default.
• W2023957899 hasRelatedWork W1722328147 @default.
• W2023957899 hasRelatedWork W1984009717 @default.
• W2023957899 hasRelatedWork W2013223170 @default.
• W2023957899 hasRelatedWork W2066747782 @default.
• W2023957899 hasRelatedWork W2376759146 @default.
• W2023957899 hasRelatedWork W2404095776 @default.
• W2023957899 hasRelatedWork W4252376471 @default.
• W2023957899 hasRelatedWork W4322772378 @default.

• next